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General features of patients at baseline.
Parameters No CKD CKD stage 4 Overall P
value
N 20 20 –
Age, years 61.4 ± 17.8 65.6 ± 14.2 0.4146
Body mass index, kg/m2 28.7 ± 6.0 26.9 ± 4.8 0.3014
Male sex (%) 12 (60%) 15 (75%) 0.5006
White ethnicity (%) 17 (85%) 15 (75%) 0.6948
Paroxysmal AF 20 (100%) 20 (100%) 1.0000
Hypertension 20 (100%) 20 (100%) 1.0000
Type 2 Diabetes Mellitus 8 (40%) 10 (50%) 0.7512
Creatinine, mg/dL 0.80 ± 0.25 2.80 ± 0.31 b0.0001
eGFR, mL/min/1.73 m2 96.7 ± 18.0 22.3 ± 4.2 b0.0001
Albumin:creatinine ratio,
mg/g
16.4 ± 3.1 83.3 ± 12.5 b0.0001
Antihypertensive
ACE-inhibitors/ARB 20 (100%) 20 (100%) 1.0000
Diuretics 20 (71%) 20 (67%) 1.0000
DHP Ca++ channel
blockers
8 (40%) 16 (80%) 0.0225
β-blockers 13 (65%) 15 (75%) 0.7311
Mean 24-hour systolic/
diastolic ABPM, mm Hg
121.4 ±
7.2/72.3 ± 4.8
124.5 ±
12.0/75.4 ± 4.0
0.1220/0.0325
Echocardiographic
parameters
Indexed left atrial
volume (mL/m2)
30.4 ± 4.1 32.2 ± 3.9 0.1630
IST (mm) 9.0 ± 1.8 9.5 ± 1.3 0.3202
LVPWT (mm) 10.5 ± 0.9 10.8 ± 1.2 0.3767
LVEF, Simpson (%) 62.4 ± 8.5 64.1 ± 9.0 0.5428
LVEDD (mm) 47.0 ± 6.3 54.4 ± 5.8 0.0004
LVESD (mm) 32.7 ± 8.6 38.8 ± 7.5 0.0219
LV mass index (g/m2) 88.7 ± 19.4 126.0 ± 16.3 b0.0001
Values are expressed as mean ± SD; ABPM, ambulatory blood pressure measurements;
ACE, angiotensin-converting enzyme; AF, atrial ﬁbrillation; ARB, angiotensin receptor
blocker; CKD, chronic kidney disease; DHP, dihydropyridine; eGFR, estimated glomerular
ﬁltration rate; LV, left ventricular; LVEDD, left ventricular end-diastolic diameter; LVEF,
left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVPWT,
left ventricular posterior wall thickness.Recently, we evaluated patients who had received a dual chamber
pacemaker implant due to sinus node disease or 3rd/2nd degree type
2 atrioventricular block in chronic kidney disease (CKD) stages 2, 3
and 4. We observed that the sustained ventricular tachycardia episodes
only occurred in patients with CKD stage 4, suggesting that themost ad-
vanced the stage of CKD, greater the incidence ofmalignant arrhythmias
[1]. Kidney disease induces cardiac remodeling including left ventricular
hypertrophy (LVH) and heart ﬁbrosis. Several clinical studies, including
those who recruited participants with mild-to-moderate reduction in
estimated glomerularﬁltration rate (eGFR), showed an independent as-
sociation between CKD and LVH [2–5]. Speciﬁcally, there is a progres-
sive increase in the prevalence of LVH, and left ventricular mass
increased when the eGFR decreases. In addition, among participants
withmore advanced kidney disease on dialysis,magnetic resonance im-
aging (MRI) with contrast demonstrates a diffuse pattern image with
gadolinium uptake suggestive of ﬁbrosis and non-ischemic cardiomy-
opathy [6]. The pathogenesis of these conditions is consideredmultifac-
torial, and the presence of commonly associated comorbidities, such as
hypertension, diabetesmellitus, and anemia, explain only part of the left
ventricular remodeling [7–9]. The molecular basis for these changes in-
cludes activation of growth factors, proto-oncogenes, plasma norepi-
nephrine, cytokines, and angiotensin II. These factors regulate
intracellular processes that accelerate cardiac hypertrophy, myocardial
ﬁbrosis, and apoptosis [10,11]. Any LVH and cardiac ﬁbrosis have been
linked to increased risk of sustained ventricular arrhythmias and predis-
position to SCD [12–16]. Structural changes can alter the electrophysio-
logical properties of the myocardium. The myocardial ﬁbrosis disrupts
the normal architecture and results in a decrease in conduction velocity
through the diseased tissue [17]. This condition can formheterogeneous
areas of conduction and depolarization that can sustain a re-entrant ar-
rhythmia, such as ventricular tachycardia [14,15,18]. These structural
changes in cardiac conduction delay ventricular activation and create
late potentials in the terminal portion of theQRS complex. Furthermore,
these low amplitude signals, which may be detected using a high-
resolution electrocardiogram, were identiﬁed in 25% of patients on dial-
ysis [19].
This transversal study involved 40 patients with CKD stage 4 and
without CKD, all of them having a history of symptomatic paroxysmal
AF (PAF). The studywas piloted in agreementwith theHelsinki declara-
tion and approved by the ethics committee of our institution. All pa-
tients signed the informed consent term before inclusion. This study
was conducted at the Hospital e Clínica São Gonçalo, Rio de Janeiro,
Brazil. Patients were recruited from July 2015 till July 2016 from the Ar-
rhythmias and Artiﬁcial Cardiac Pacing Service of the same hospital. En-
rolled patients met the following criteria: (i) a heart with an ejection
fraction of N50% as measured by echocardiography (Simpson's meth-
od), (ii) PAF (deﬁned as AF episodes lasting b7 days with spontaneoushttp://dx.doi.org/10.1016/j.ijcme.2016.09.005
2214-7624/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access articltermination) registered on ECG or 24-h Holter monitoring, (iii) aged
18 to 80 years, (iv) patients with CKD stage 4: estimated glomerular ﬁl-
tration rate (eGFR) between 15 and 29mL/min/1.73m2, and noCKD pa-
tients: eGFR N60 mL/min/1.73 m2 calculated using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation [20] (without
microalbuminuria), and (v) the capacity to read, comprehend and sign
the informed consent form, and attend the study. Patients with any of
the following were excluded: (i) pregnancy; (ii) valvular disease with
signiﬁcant adverse sequelae; (iii) unstable angina, myocardial infarc-
tion, transient ischemic attack or stroke previously; (iv) psychiatric dis-
ease; (v) the inability to bemonitored clinically after the procedure; (vi)
a known addiction to alcohol or drugs that affects the intellect; (vii)
congestive heart failure (symptoms of functional class II to IV heart fail-
ure on the New York Heart Association scale).e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 2
Relative risk for absence of voltage in the left ventricle in patients on CKD stage 4 vs. pa-
tients without CKD, evaluated by Fisher's exact test.
Absence of voltage Relative risk 95% conﬁdence interval P value
Left ventricular septum 4.889 2.232–12.300 b0.0001
Left ventricular lateral free wall 3.500 3.293–5.594 b0.0001
Left ventricular anterior wall 2.852 1.471–6.097 0.0036
Left ventricular posterior wall 3.667 1.805–8.395 0.0003
CKD, chronic kidney disease.
18 Letter to the EditorThe subjects were divided into two groups according to their KDIGO
CKD status, and the procedure performed: CKD stage 4 patients
underwent pulmonary veins isolation (PVI) (n = 20), and no CKD pa-
tients underwent PVI (n = 20). After the PVI, a left ventricular voltage
map was constructed, and zones without voltage were compared be-
tween groups.
The AF ablation procedure has been described in detail previously
[21]. All patients underwent complete PVI using a three-dimensional
mapping system (EnSite Velocity; St. Jude Medical) without additional
ablation lesion sets or lines. Patients still in AF at the end of the proce-
dure were converted to sinus rhythm by cardioversion. The left ventric-
ular voltagemapwas constructed also using the EnSite Velocity system,
and the left ventricle was divided into 4 parts: septum, lateral free wall,
anterior wall, and posterior wall, aiming to ﬁnd areas without voltage
(zones of scar).
The results are expressed as a mean and standard deviation for nor-
mally distributed data and as median with interquartile range other-
wise. Comparisons between two-paired values were performed with
the paired t-test in cases of a Gaussian distribution and by theWilcoxon
test otherwise. For normality of distribution, D'Agostino-Pearson test
was used. Comparisons between more than two-paired values were
made by repeated-measures analysis of variance or by Kruskal–Wallis
analysis of variance as appropriate, complemented by the post-hoc
Tukey test. Categorical variables were compared with Fisher's exact
test. A two-tailed P-value b 0.05 was used as a criterion for statisticalFig. 1. Absence of voltage (%) in patients with CKD stage 4 (n= 20) vs. no CKD patients (n = 2
(D) posterior wall; CKD, chronic kidney disease.signiﬁcance. All statistical analyses were performed using the program
Graphpad Prism v 7.0 (Graphpad Software, La Jolla, CA, USA).
The general features and the baseline echocardiographic parameters
of the two groups of patients are listed in Table 1. Comparing patients
with CKD stage 4 vs. patients without CKD, we noted that the relative
risk of the absence of voltage is higher in the ﬁrst group, making this
the most susceptible group to present ventricular arrhythmias, as
shown in Table 2. In the left ventricular septum (Fig. 1A), lateral free
wall (Fig. 1B), anteriorwall (Fig. 1C) and posteriorwall (Fig. 1D), the pa-
tientswith CKD stage 4 presented 80%, 60%, 70%, and 75% of zoneswith-
out voltage, respectively, vs. no CKD patients that presented 10%, 0%,
20%, and 15% of areas without voltage, respectively (P b 0.0001,
P b 0.0001, P = 0.0036, and P = 0.0003, respectively).
The presence of AF hampersmeasurement of LV ejection fraction be-
cause of tachycardia and beat-to-beat (i.e., R-to-R) LV ﬁlling variability.
Ourmeasurements could have been less precise becausewe did not use
a three-dimensional single-beat ultrasound system. The inability to per-
form cardiac gadolinium-enhanced magnetic resonance image in pa-
tients with CKD stage 4, due to the nephrotoxicity of a component of
this substance is an important limitation because it could conﬁrm exact-
ly the zones of scar detected by the voltage our map.
Patientswith CKD stage 4 seem to bemore susceptible to ventricular
arrhythmias than patients without CKD, due to a larger absence of volt-
age in the left ventricular walls of the ﬁrst ones.Conﬂict of interest
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